Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 39393406

Drug Profile

JNJ 39393406

Alternative Names: JNJ-39393406

Latest Information Update: 08 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen Pharmaceutica; National Institutes of Health (USA); University of Pittsburgh
  • Class Antidementias; Nootropics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Depressive disorders; Schizophrenia; Smoking withdrawal

Most Recent Events

  • 08 Sep 2021 Discontinued - Phase-II for Depressive disorders in Moldova and Romania (PO) before September 2021 (Johnson & Johnson Pharmaceutical Research & Development's pipeline, September 2021)
  • 08 Sep 2021 Discontinued - Phase-II for Smoking withdrawal in USA (PO) before September 2021 (Johnson & Johnson Pharmaceutical Research & Development's pipeline, September 2021)
  • 15 Feb 2016 Johnson & Johnson Pharmaceutical Research plans the exploratory phase II JNJ-DEP trial for Depressive disorders in Romania (PO, Capsule) (NCT02677207)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top